A brain‐targeted, stabilized KLK6 variant with a longer half‐life (R80Q) degrades α‐syn in oligodendrocytes and astrocytes, ameliorates myelin sheath deficiency in the corpus callosum and improves behavioral deficits in a PD mouse model obtained via α‐syn overexpression (Spencer et al., 2015). Here, KLK6 is linked to Parkinson disease.